{"id":70770,"date":"2026-05-12T10:58:38","date_gmt":"2026-05-12T10:58:38","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70770"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"hgh-191aa","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/hgh-191aa\/","title":{"rendered":"HGH 191AA"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es la HGH 191AA?<\/h3>\n<p style=\"margin: 0;\"><strong>HGH 191AA<\/strong> is recombinant human growth hormone in its full 191-amino-acid native sequence form (somatropin), a 22-kDa pituitary peptide hormone produced by recombinant DNA technology to exactly match the endogenous human GH polypeptide. It acts directly on the growth hormone receptor (GHR) to activate JAK2\/STAT5 signalling and drive hepatic IGF-1 production. This is the modern pharmaceutical-quality form (191AA) as opposed to the obsolete bacterial 192AA recombinant variant. Supplied in 10\u201340\u00a0IU lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">12629-01-5 (somatropina) \/ 96827-07-5 (somatropina recombinante)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prote\u00edna recombinante \u2014 secuencia de 191 amino\u00e1cidos de la hormona de crecimiento humana nativa (somatropina); DCI: somatropina<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">22,124 Da (~22 kDa)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estructura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Cadena polipept\u00eddica \u00fanica de 191 amino\u00e1cidos plegada en una topolog\u00eda can\u00f3nica de haz de cuatro h\u00e9lices, estabilizada por dos puentes disulfuro intramoleculares (Cys53\u2013Cys165 y Cys182\u2013Cys189). La designaci\u00f3n 191AA distingue la forma farmac\u00e9utica moderna de calidad de la variante obsoleta 192AA recombinante bacteriana que portaba una metionina extra en el extremo N-terminal.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Actividad unitaria<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Aproximadamente 3 UI por mg de HGH recombinante 191AA (unidades internacionales, est\u00e1ndar de la OMS)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prote\u00edna recombinante liofilizada (polvo blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226598% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar en ~14 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida \u2014 las prote\u00ednas recombinantes son particularmente sensibles a la desnaturalizaci\u00f3n por ciclos de congelaci\u00f3n-descongelaci\u00f3n.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada). Prote\u00edna transportadora (BSA, 0,1%) opcional para diluciones de trabajo para minimizar p\u00e9rdidas por adsorci\u00f3n.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es la HGH 191AA?<\/h2>\n<p><strong>HGH 191AA<\/strong> is recombinant human growth hormone (somatropin) in the 191-amino-acid native human sequence form. It is produced by recombinant DNA technology and matches the endogenous human GH polypeptide exactly \u2014 same 191 amino acids, same four-helix bundle three-dimensional structure, same two intramolecular disulfide bonds at Cys53\u2013Cys165 and Cys182\u2013Cys189. The 191AA designation specifically distinguishes the modern pharmaceutical-quality recombinant form from the older 192AA variant produced in bacterial expression systems, which carried an additional N-terminal methionine that introduced minor antigenicity differences and has been largely phased out of studies and clinical use. HGH is the principal peptide hormone secreted by somatotroph cells of the anterior pituitary in episodic pulses, with peak amplitudes occurring during early slow-wave sleep and following intense exercise. Endogenous secretion is regulated upstream by hypothalamic GHRH (positive) and somatostatin (negative). The recombinant 191AA form has empirical molecular weight 22,124\u00a0Da, INN somatropin, CAS number 12629-01-5 for the native protein and 96827-07-5 for the recombinant form. Standard unit activity for recombinant 191AA HGH is approximately 3\u00a0IU per mg according to the WHO International Standard. The compound is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. HGH is the most stringently regulated of all peptides in many jurisdictions and is approved for specific medical indications (paediatric GH deficiency, adult GH deficiency, Turner syndrome, idiopathic short stature, AIDS wasting, short bowel syndrome) only under prescription. For peptides that stimulate endogenous GH release rather than supplying exogenous GH, see our <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a>, <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a>, y <a href=\"https:\/\/medsbase.com\/es\/ipamorelin\/\">Ipamorelina<\/a> p\u00e1ginas de productos. <\/p>\n<h2>Mecanismo de acci\u00f3n \u2014 Se\u00f1alizaci\u00f3n del receptor de hormona de crecimiento y el eje GH\/IGF<\/h2>\n<p>What makes HGH 191AA mechanistically distinctive among peptides is that it is the <strong>ligando ex\u00f3geno directo<\/strong> for the growth hormone receptor \u2014 not an analog, not a secretagogue, but the native polypeptide itself. The downstream signalling cascade has been characterised across decades of published studies:<\/p>\n<ul>\n<li><strong>Uni\u00f3n al receptor de hormona de crecimiento (GHR) y homodimerizaci\u00f3n<\/strong> \u2014 La HGH se une a una sola mol\u00e9cula de GHR con alta afinidad e induce la homodimerizaci\u00f3n con una segunda unidad receptora, formando el complejo ligando-receptor bioactivo 1:2. El receptor dimerizado recluta la quinasa Janus 2 citoplasm\u00e1tica (JAK2) al motivo de la caja receptora intracelular, lo que lleva a la trans-fosforilaci\u00f3n de JAK2 y del propio receptor. Este es el mecanismo de activaci\u00f3n can\u00f3nico del receptor de citoquinas Tipo I.<\/li>\n<li><strong>Activaci\u00f3n del factor de transcripci\u00f3n JAK2\/STAT5<\/strong> \u2014 La JAK2 fosforilada fosforila el Transductor de Se\u00f1al y Activador de la Transcripci\u00f3n 5 (STAT5), principalmente STAT5b, que luego se dimeriza y se transloca al n\u00facleo donde se une a los promotores de genes sensibles a GH. El principal resultado transcripcional es la inducci\u00f3n de la expresi\u00f3n de IGF-1 (Factor de Crecimiento Similar a la Insulina 1) en hepatocitos \u2014 el principal efector endocrino de los efectos perif\u00e9ricos promotores del crecimiento de la GH. Otros genes sensibles a GH incluyen prote\u00ednas SOCS (retroalimentaci\u00f3n negativa), CIS y un programa de genes de s\u00edntesis de prote\u00ednas hep\u00e1ticas.<\/li>\n<li><strong>Efectos tisulares directos e indirectos (mediados por IGF-1)<\/strong> \u2014 La GH tiene dos modos principales de acci\u00f3n. <em>Efectos directos<\/em>: lipolysis at adipocytes, glucose-counter-regulatory effects opposing insulin in muscle and liver, and direct anabolic signalling at GHR-expressing tissues including chondrocytes (in long-bone growth-plate studies) and immune cells. <em>Efectos indirectos a trav\u00e9s de IGF-1<\/em>: hepatic IGF-1 acts at the IGF-1 receptor on essentially every cell type to drive Akt\/mTOR-mediated protein synthesis, cell proliferation, and survival signalling. The compound <a href=\"https:\/\/medsbase.com\/es\/igf-1-lr3\/\">IGF-1 LR3<\/a> es la herramienta can\u00f3nica de receptor directo de IGF utilizada para distinguir los efectos directos de la GH de los efectos descendentes mediados por IGF-1.<\/li>\n<\/ul>\n<p>HGH has a relatively short plasma half-life (~3\u20135 hours following subcutaneous administration of the native protein) due to renal filtration and proteolytic clearance. The pulsatile pattern of endogenous secretion is a defining feature of the GH axis \u2014 tonic continuous exposure to GH produces different downstream gene-expression patterns than pulsatile exposure, an important consideration in protocol design. Subcutaneous administration is the standard administration route. For endogenous-pulse-pattern studies, secretagogues like <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a>, <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295<\/a>, y <a href=\"https:\/\/medsbase.com\/es\/ipamorelin\/\">Ipamorelina<\/a> preservan la firma puls\u00e1til natural; para la farmacolog\u00eda directa del receptor de GH, la HGH ex\u00f3gena proporciona el est\u00edmulo m\u00e1s limpio. <\/p>\n<h2>Published Evidence<\/h2>\n<p>HGH 191AA is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacolog\u00eda del eje de la hormona de crecimiento<\/strong> \u2014 direct GHR signalling, JAK2\/STAT5 phosphorylation kinetics, downstream IGF-1 induction; canonical peptide for the GH side of the GH\/IGF-1 axis<\/li>\n<li><strong>IGF-1 induction studies<\/strong> \u2014 expresi\u00f3n g\u00e9nica de IGF-1 hep\u00e1tico, din\u00e1mica de IGF-1 circulante, regulaci\u00f3n de prote\u00ednas de uni\u00f3n a IGF (IGFBP); comparador para <a href=\"https:\/\/medsbase.com\/es\/igf-1-lr3\/\">IGF-1 LR3<\/a>-based studies that bypasses the GH step<\/li>\n<li><strong>Anabolic signalling studies<\/strong> \u2014 s\u00edntesis de prote\u00ednas en m\u00fasculo esquel\u00e9tico a trav\u00e9s de Akt\/mTOR (en gran parte mediada por IGF-1), se\u00f1alizaci\u00f3n de condrocitos en placas de crecimiento \u00f3seo, lip\u00f3lisis en tejido adiposo<\/li>\n<li><strong>Hepatic metabolism studies<\/strong> \u2014 producci\u00f3n de glucosa en el h\u00edgado, metabolismo de l\u00edpidos, respuesta transcripcional espec\u00edfica de hepatocitos a la estimulaci\u00f3n con GH<\/li>\n<li><strong>Modelos precl\u00ednicos de deficiencia de GH<\/strong> \u2014 estudios de rescate en roedores hipofisectomizados, modelos de ratones enanos Snell y Ames, caracterizaci\u00f3n de knockout transg\u00e9nico de GHR<\/li>\n<li><strong>Sleep and circadian rhythm support<\/strong> \u2014 relaci\u00f3n entre la arquitectura del sue\u00f1o y la secreci\u00f3n puls\u00e1til de GH, dependencia de GH en el sue\u00f1o de ondas lentas<\/li>\n<li><strong>Comparative GH-axis studies<\/strong> \u2014 comparativa con an\u00e1logos de GHRH (\",\") y secretagogos de hormona de crecimiento (\",\") que producen pulsos end\u00f3genos de GH en lugar de reemplazo ex\u00f3geno de GH<a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a>, <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295<\/a>Investigaci\u00f3n sobre regeneraci\u00f3n tisular y cicatrizaci\u00f3n de heridas<a href=\"https:\/\/medsbase.com\/es\/ipamorelin\/\">Ipamorelina<\/a>, <a href=\"https:\/\/medsbase.com\/es\/ghrp-6\/\">GHRP-6<\/a>, <a href=\"https:\/\/medsbase.com\/es\/ghrp-2\/\">GHRP-2<\/a>\u2014 literatura publicada sobre los efectos de GH en modelos de lesiones por quemaduras, recuperaci\u00f3n quir\u00fargica y regeneraci\u00f3n tisular; relaci\u00f3n con<\/li>\n<li><strong>Tissue regeneration and wound healing studies<\/strong> \u2014 published literature on GH effects in burn injury models, surgical recovery, and tissue regeneration; relationship to <a href=\"https:\/\/medsbase.com\/es\/tb-500\/\">TB-500<\/a> y <a href=\"https:\/\/medsbase.com\/es\/bpc-157\/\">BPC-157<\/a> healing peptide studies<\/li>\n<li><strong>Endocrinology and aging studies<\/strong> \u2014 somatopause and age-related GH decline, comparative studies of GH replacement vs GH-axis stimulation in aging study models.<\/li>\n<\/ul>\n<p>Para un contexto m\u00e1s amplio sobre d\u00f3nde se sit\u00faa la HGH 191AA dentro del panorama de p\u00e9ptidos del eje de crecimiento, consulte <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> y <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> como comparadores del eje GHRH, <a href=\"https:\/\/medsbase.com\/es\/ipamorelin\/\">Ipamorelina<\/a> como comparador selectivo de GHS, y <a href=\"https:\/\/medsbase.com\/es\/igf-1-lr3\/\">IGF-1 LR3<\/a> como agonista del receptor de IGF descendente. Explore el <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks HGH 191AA in five lyophilized vial sizes calibrated by international units (IU). Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentraci\u00f3n del vial (IU)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Masa aproximada<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 IU<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~3,3 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dosificaci\u00f3n piloto, titulaci\u00f3n de bajo nivel, protocolos de ciclo corto<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15 IU<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~5 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, mid-titration arm<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>24\u00a0IU<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~8\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle studies, higher-dose titration arm<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>36\u00a0IU<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~12\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de varias semanas con un solo vial, menor volumen de reconstituci\u00f3n por dosis<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40\u00a0IU<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~13.3\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bulk packs vial, lowest per-IU cost, multi-cohort studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All five strengths are the same chemical form (lyophilized recombinant 191AA somatropin, \u226598% HPLC purity). The IU labelling convention is the standard for HGH studies and clinical literature; the approximate mg equivalents are provided for users calibrating dose against mg-based literature. Higher-IU vials require smaller reconstitution volumes per unit dose, useful for minimising injection volume in rodent protocols or running extended-cycle studies from a single vial. <\/p>\n<h2>Comparativa \u2014 HGH 191AA frente a Sermorelina<\/h2>\n<p>HGH 191AA y <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> represent the two opposing pharmacological approaches to GH-axis studies: exogenous GH replacement vs endogenous GH stimulation. The comparison is one of the most-cited in growth-axis studies design because the two approaches answer different studies questions and produce qualitatively different downstream phenotypes. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH 191AA<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Sermorelin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Qu\u00e9 es<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GH ex\u00f3gena en s\u00ed misma (recombinante)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">An\u00e1logo de GHRH(1-29) \u2014 estimula la GH end\u00f3gena<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longitud<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">191 amino\u00e1cidos (~22 kDa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">29 amino\u00e1cidos (~3 kDa)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Modo de acci\u00f3n<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Agonismo directo del GHR (reemplazo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Agonismo del receptor de GHRH hipotal\u00e1mico (estimulaci\u00f3n)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Patr\u00f3n de pulsos de GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Exposici\u00f3n t\u00f3nica tras cada inyecci\u00f3n<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Puls\u00e1til (preserva el ritmo natural)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Retroalimentaci\u00f3n negativa<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Evitado (suprime las somatotrofas end\u00f3genas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Preservado (la somatostatina sigue activa)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vida media plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~3\u20135 horas (SC)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~10\u201320 minutos (muy corto)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Uso cl\u00ednico aprobado<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">M\u00faltiples indicaciones aprobadas (Genotropin, Humatrope, Norditropin, etc.)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aprobaci\u00f3n hist\u00f3rica de la FDA para GHD pedi\u00e1trico (Geref); discontinuado<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosis t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1\u20138\u00a0UI por administraci\u00f3n<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">100\u2013500\u00a0mcg por administraci\u00f3n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in direct GHR pharmacology, IGF-1 induction kinetics, or replacing GH in deficiency models, HGH 191AA is the canonical tool because it provides the exogenous ligand directly. For studies interested in physiological pulsatile GH dynamics, hypothalamic-pituitary-axis pharmacology, or any protocol where preserving the natural somatostatin feedback loop matters, <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> (y el relacionado <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a>) provide the upstream-stimulation alternative. Many published studies designs use both in parallel arms to dissect direct GH effects from secretagogue-stimulated endogenous GH effects. <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> almacene los viales liofilizados refrigerados a 2\u20138\u00a0\u00b0C en el embalaje original para el stock de trabajo a corto plazo. Para almacenamiento a largo plazo sin abrir, congele a \u221220\u00a0\u00b0C. La HGH recombinante liofilizada es estable bajo refrigeraci\u00f3n hasta 24 meses y a \u221220\u00a0\u00b0C hasta 36 meses. El estado de plegamiento de cuatro h\u00e9lices se preserva en la forma liofilizada. Evite los ciclos de congelaci\u00f3n-descongelaci\u00f3n en el polvo liofilizado. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inyecte agua bacteriost\u00e1tica por la pared lateral del vial (no directamente sobre el pastel liofilizado). Los vol\u00famenes de reconstituci\u00f3n recomendados var\u00edan seg\u00fan la fuerza del vial \u2014 para un vial de 10\u00a0UI, 1.0\u00a0mL de agua bacteriost\u00e1tica produce una concentraci\u00f3n de trabajo de 10\u00a0UI\/mL; para un vial de 36\u00a0UI, 1.5\u00a0mL produce 24\u00a0UI\/mL. Agite suavemente \u2014 no <strong>ajuste<\/strong> sacuda \u2014 y permita 5\u201310 minutos para la disoluci\u00f3n completa. Las prote\u00ednas recombinantes se disuelven m\u00e1s lentamente que los p\u00e9ptidos peque\u00f1os; no apresure el paso de disoluci\u00f3n. La agitaci\u00f3n vigorosa puede alterar la estructura de cuatro h\u00e9lices y reducir la actividad. Una soluci\u00f3n correctamente reconstituida debe ser clara e incolora sin part\u00edculas visibles. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> almacene refrigerado a 2\u20138\u00a0\u00b0C y use dentro de los 14 d\u00edas para una estabilidad \u00f3ptima \u2014 algo m\u00e1s corto que el per\u00edodo de 30 d\u00edas para p\u00e9ptidos sint\u00e9ticos m\u00e1s peque\u00f1os porque la prote\u00edna de cuatro h\u00e9lices m\u00e1s grande es m\u00e1s susceptible a p\u00e9rdidas por adsorci\u00f3n superficial y desamidaci\u00f3n lenta. No congele la soluci\u00f3n reconstituida \u2014 los ciclos de congelaci\u00f3n-descongelaci\u00f3n producen agregaci\u00f3n y p\u00e9rdida de actividad biol\u00f3gica. Deseche cualquier vial que muestre turbidez, precipitado o decoloraci\u00f3n. Para diluciones de trabajo largas por debajo de 0.1\u00a0mg\/mL (~0.3\u00a0UI\/mL), la prote\u00edna transportadora (BSA al 0.1% de concentraci\u00f3n final) minimiza las p\u00e9rdidas por adsorci\u00f3n. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is HGH 191AA used for in studies?<\/h3>\n<p>HGH 191AA is used in studies investigating direct growth hormone receptor pharmacology, JAK2\/STAT5 signalling, hepatic IGF-1 induction, anabolic signalling in muscle and bone, hepatic metabolism, sleep-GH-axis relationships, GH-deficiency preclinical models, and comparative GH-axis pharmacology against GHRH analogs and growth hormone secretagogues. It is the canonical exogenous GH tool. The pharmaceutical-grade HGH 191AA sold here is <strong>ajuste<\/strong> FDA-approved for non-clinical human use and is supplied strictly for clinical studies use only. <\/p>\n<h3>\u00bfCu\u00e1l es la diferencia entre la HGH 191AA y la 192AA?<\/h3>\n<p>The 191AA form is the modern pharmaceutical-quality recombinant human growth hormone matching the exact native human sequence (191 amino acids). The 192AA form was an older bacterial-recombinant variant with an additional N-terminal methionine residue (192 amino acids total) that was used in early pharmaceutical development before mammalian-cell expression systems became standard. The extra methionine produced minor antigenicity in some patient populations and the 192AA form has been largely phased out of both studies and clinical use. All pharmaceutical-grade HGH from MedsBase is the 191AA native-sequence form. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia la HGH 191AA del Sermorelina?<\/h3>\n<p>La HGH 191AA es la propia hormona de crecimiento ex\u00f3gena \u2014 el ligando activo del receptor. <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> is a 29-amino-acid analog of GHRH (growth hormone releasing hormone) that stimulates the pituitary to release ENDOGENOUS GH. The downstream effects are similar in direction but qualitatively different: HGH produces tonic GHR exposure following each injection and bypasses pituitary feedback, while sermorelin produces a pulsatile GH release pattern and preserves natural somatostatin feedback regulation. Studies designs typically use one or the other depending on whether the question is about direct GHR pharmacology (HGH) or hypothalamic-pituitary-axis dynamics (sermorelin). <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia la HGH 191AA del IGF-1 LR3?<\/h3>\n<p>La HGH 191AA act\u00faa sobre el receptor de GH, lo que impulsa la producci\u00f3n de IGF-1 por el h\u00edgado como principal efector descendente. <a href=\"https:\/\/medsbase.com\/es\/igf-1-lr3\/\">IGF-1 LR3<\/a> bypasses this step and acts directly on the IGF-1 receptor. HGH studies the full GH\/IGF-1 axis including the upstream liver-mediated IGF-1 induction; IGF-1 LR3 isolates the IGF-receptor pharmacology and the direct downstream Akt\/mTOR anabolic signalling. Both compounds are frequently used in parallel arms of the same studies design to dissect direct GH effects from IGF-1-mediated effects. <\/p>\n<h3>What is the typical HGH 191AA dose?<\/h3>\n<p>Published preclinical studies dose ranges are typically 1\u20138\u00a0IU per administration in rodent and primate models, given subcutaneously once daily or pulsed to mimic endogenous secretion patterns. A 10\u00a0IU vial reconstituted with 1.0\u00a0mL bacteriostatic water yields 10\u00a0IU\/mL \u2014 0.1\u00a0mL equals 1\u00a0IU, 0.2\u00a0mL equals 2\u00a0IU. The conversion factor is approximately 3\u00a0IU per mg of recombinant 191AA HGH (WHO international standard). <\/p>\n<h3>\u00bfEst\u00e1 la HGH 191AA aprobada por la FDA?<\/h3>\n<p>Pharmaceutical recombinant 191AA HGH (somatropin) is FDA-approved under multiple brand names (Genotropin, Humatrope, Norditropin, Saizen, Omnitrope, Nutropin and others) for specific medical indications including paediatric growth hormone deficiency, adult GH deficiency, Turner syndrome, idiopathic short stature, AIDS-associated wasting, and short bowel syndrome \u2014 only under prescription and supervision by an endocrinologist. It is the most stringently regulated of all peptides in many jurisdictions. <\/p>\n<h3>\u00bfC\u00f3mo se debe almacenar la HGH 191AA?<\/h3>\n<p>Viales liofilizados: refrigerados a 2\u20138 \u00b0C para stock de trabajo a corto plazo, o \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Soluci\u00f3n reconstituida: refrigerada a 2\u20138 \u00b0C, usar dentro de 14 d\u00edas (menos tiempo que los p\u00e9ptidos peque\u00f1os t\u00edpicos debido a que la estructura de cuatro h\u00e9lices es m\u00e1s susceptible a adsorci\u00f3n superficial y desamidaci\u00f3n lenta). No congelar la soluci\u00f3n reconstituida \u2014 los ciclos de congelaci\u00f3n-descongelaci\u00f3n producen agregaci\u00f3n y p\u00e9rdida de actividad. Proteger siempre de la luz directa. <\/p>\n<h3>\u00bfC\u00f3mo reconstituyo la HGH 191AA?<\/h3>\n<p>Siga el procedimiento de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no sobre el polvo liofilizado), agite suavemente y deje reposar 5\u201310 minutos para una disoluci\u00f3n completa. No agite el vial \u2014 la agitaci\u00f3n vigorosa puede desnaturalizar prote\u00ednas recombinantes y causar agregaci\u00f3n. Una soluci\u00f3n correctamente reconstituida es clara e incolora. Para un vial de 1 mg + 1,0 mL de diluyente, la concentraci\u00f3n de trabajo es de 1 mg\/mL. <strong>ajuste<\/strong> Agitar suavemente el vial \u2014 la agitaci\u00f3n vigorosa puede alterar la estructura de cuatro h\u00e9lices y reducir la actividad biol\u00f3gica. Una soluci\u00f3n correctamente reconstituida es transparente e incolora, sin part\u00edculas visibles. <\/p>\n<h3>\u00bfQu\u00e9 concentraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase carries HGH 191AA in 10\u00a0IU, 15\u00a0IU, 24\u00a0IU, 36\u00a0IU, and 40\u00a0IU lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at \u226598% HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>\u00bfPor qu\u00e9 la HGH se mide en UI en lugar de mg?<\/h3>\n<p>International Units (IU) are the standard measurement for biological-activity-based labelling of protein hormones, established by the WHO International Standard. For recombinant 191AA HGH, the conversion factor is approximately 3\u00a0IU per mg. The IU labelling convention is preferred because it directly references biological potency rather than mass, which is more reproducible across different recombinant production batches that may vary slightly in glycosylation state, deamidation profile, and folding-state heterogeneity. Both IU and mg are valid; the IU is the dominant unit in clinical and literature. <\/p>\n<h3>\u00bfPor qu\u00e9 la especificaci\u00f3n de pureza es del 98% en lugar del 99%?<\/h3>\n<p>Recombinant proteins like HGH cannot always achieve the \u226599% HPLC purity standard typical of small synthetic peptides because of inherent heterogeneity in any recombinant expression system \u2014 minor variants in folding state, deamidation isoforms, and other related species appear as related peaks on HPLC that are not impurities but isoforms of the target protein. \u226598% HPLC purity is a strong pharmaceutical-grade specification for recombinant 191AA HGH, intermediate between the 95% common for larger glycoproteins like <a href=\"https:\/\/medsbase.com\/es\/follistatin-344\/\">Follistatina 344<\/a> y el 99% com\u00fan para p\u00e9ptidos sint\u00e9ticos peque\u00f1os. <\/p>\n<h3>Does HGH 191AA cause side reported effects?<\/h3>\n<p>The principal on-target effects of HGH in study models are anabolic and metabolic: increased IGF-1 levels, increased lean body mass, decreased adiposity, transient insulin resistance, sodium and water retention, and increased mitogenic signalling. At supraphysiological exposures, off-target effects include carpal tunnel symptoms in primate models, glucose dysregulation, and (with chronic exposure) joint and soft-tissue overgrowth. The very strict regulatory framework around HGH for human use reflects these on-target risks at non-physiological doses. <\/p>\n<h3>\u00bfCu\u00e1l es la vida media del HGH 191AA?<\/h3>\n<p>In preclinical studies, recombinant HGH has a plasma half-life of approximately 3\u20135 hours following subcutaneous administration. The relatively short half-life reflects renal filtration (a 22-kDa protein is at the boundary of the glomerular filtration cutoff) and proteolytic clearance. Tissue half-life is longer because GHR-bound HGH persists at the cell surface for some time before internalisation. For protocols requiring sustained exposure, repeated daily dosing or specialised long-acting formulations would be needed; the standard recombinant 191AA form does not provide multi-day exposure from a single injection. <\/p>\n<h3>How long does HGH 191AA take to show effects in preclinical studies?<\/h3>\n<p>Los efectos agudos sobre la fosforilaci\u00f3n de JAK2\/STAT5 y el programa de transcripci\u00f3n inmediato sensible a GH son detectables en horas tras la administraci\u00f3n. La inducci\u00f3n hep\u00e1tica de IGF-1 alcanza su pico en 24 horas. Los efectos sobre la composici\u00f3n corporal (masa magra, masa adiposa) t\u00edpicamente se vuelven estad\u00edsticamente significativos tras 2-4 semanas de dosificaci\u00f3n regular en modelos de roedores y contin\u00faan acumul\u00e1ndose hasta las 8-12 semanas de administraci\u00f3n continua. <\/p>\n<h3>\u00bfPuedo pedir HGH 191AA para env\u00edo internacional?<\/h3>\n<p>S\u00ed, donde las regulaciones locales lo permitan. MedsBase env\u00eda HGH 191AA a todo el mundo desde nuestra red de env\u00edos dedicada a p\u00e9ptidos. Los pedidos que solo contienen p\u00e9ptidos califican para nuestro servicio de env\u00edo independiente de p\u00e9ptidos. Todos los pedidos se env\u00edan en embalaje con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestro <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. Note that HGH is the most stringently regulated peptide in many jurisdictions \u2014 please verify that local laws permit acquisition in your destination country before ordering. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Growth-Axis, GH-Release, and Anabolic Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 An\u00e1logo de GHRH(1-29) \u2014 estimula la liberaci\u00f3n end\u00f3gena de GH<\/li>\n<li><a href=\"\/es\/cjc-1295-with-dac\/\"><strong>CJC-1295 con DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 canonical long-half-life GHRH use<\/li>\n<li><a href=\"\/es\/ipamorelin\/\"><strong>Ipamorelina<\/strong><\/a> \u2014 Secretagogo de hormona de crecimiento selectivo \u2014 pulso limpio de GH sin cortisol\/prolactina<\/li>\n<li><a href=\"\/es\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 An\u00e1logo recombinante de IGF-1 de arginina larga \u2014 omite el paso de GH<\/li>\n<li><a href=\"\/es\/ghrp-6\/\"><strong>GHRP-6<\/strong><\/a> \u2014 First-generation hexapeptide GHS \u2014 ghrelin-axis GH release studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explora el eje de la hormona de crecimiento<\/strong><\/p>\n<p style=\"margin: 0;\">Explora toda la <a href=\"https:\/\/medsbase.com\/es\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, con compuestos relacionados del eje GH incluyendo <a href=\"https:\/\/medsbase.com\/es\/sermorelin\/\">Sermorelin<\/a> y <a href=\"https:\/\/medsbase.com\/es\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for endogenous-pulse studies, <a href=\"https:\/\/medsbase.com\/es\/ipamorelin\/\">Ipamorelina<\/a> for selective GHS studies, and <a href=\"https:\/\/medsbase.com\/es\/igf-1-lr3\/\">IGF-1 LR3<\/a> para el brazo descendente del eje IGF.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Hormona de crecimiento humana recombinante de 191 aa (somatropina)<br \/>\n\u2705 Secuencia humana nativa \u2014 forma farmac\u00e9utica moderna de calidad<br \/>\n\u2705 Agonista directo del receptor de GH (~22 kDa)<br \/>\n\u2705 Conversi\u00f3n est\u00e1ndar ~3 UI por mg<br \/>\n\u2705 Pureza \u226598% por HPLC, COA bajo solicitud<\/p>\n<p><strong>HGH 191AA<\/strong> es una prote\u00edna recombinante.<\/p>","protected":false},"featured_media":70958,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6288,5441],"class_list":["post-70770","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-hgh","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70770"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70958"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70770"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70770"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70770"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}